- Global Pharma News & Resources

Igenbio Provides Automated Variant Analysis

Igenbio, Inc. announced today the expansion of variant analysis service offerings. Igenbio’s comprehensive variant analysis service answers pressing questions in genome differences reflecting changes to metabolic pathways and genetic associations relevant to disease- or cancer-causing variations. Igenbio’s flagship product ERGO 2.0 enables researchers to deepen the analysis of variations with interactive visualizations enabling industrial, academic, and medical scientists to rapidly uncover hidden genetic variations and develop diagnostic biomarkers.

“Research scientists can use ERGO’s Variant workflow by simply “dragging-and-dropping” the sequence files into ERGO and receiving scientifically rigorous results in minutes. Discover single nucleotide polymorphisms (SNPs), insertions, deletions (INDELS), along with their functional relevance and deleterious effects. ERGO does it all for you: from sequence quality assessments to annotating variant effects of any genome. This furthers our goal of making the best bioinformatics analysis available to all researchers, regardless of their computer experience.”, says Benjamin Vaisvil, VP, Bioinformatics and Software Development at Igenbio, Inc.

About Igenbio

Chicago-based Igenbio, Inc. specializes in research in genomics, bioinformatics, and transcriptomics. Igenbio, Inc. serves a broad customer base across industry, academic and government institutions. ERGO 2.0 integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, with tools and workflows for common bioinformatics tasks. Our goal is to make the best scientific analysis available to all researchers.

View source version on

Editor Details

Last Updated: 06-Dec-2018